News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Cipla Ltd. Tells Merck & Co., Inc. its Anti-AIDS Drug Too Costly in India
April 4, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MC -- Pharma major Cipla has applied for a "voluntary license" for Merck's anti-HIV drug Isentress saying the drug is exorbitantly priced and is inaccessible to needy patients in India.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Merck & Co.
MORE ON THIS TOPIC
Job Trends
Takeda cuts send layoffs soaring in May, rising year over year
May 19, 2026
·
4 min read
·
Angela Gabriel
Weight loss
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
May 7, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly investing billions to prepare for overseas oral GLP-1 launches
April 14, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
April 13, 2026
·
2 min read
·
Nick Paul Taylor
